OVAS vs. FGEN, ADAG, IMUX, ABEO, COYA, RZLT, CLRB, DMAC, VTGN, and CRVS
Should you be buying OvaScience stock or one of its competitors? The main competitors of OvaScience include FibroGen (FGEN), Adagene (ADAG), Immunic (IMUX), Abeona Therapeutics (ABEO), Coya Therapeutics (COYA), Rezolute (RZLT), Cellectar Biosciences (CLRB), DiaMedica Therapeutics (DMAC), Vistagen Therapeutics (VTGN), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "medical" sector.
FibroGen (NASDAQ:FGEN) and OvaScience (NASDAQ:OVAS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking and earnings.
In the previous week, FibroGen had 1 more articles in the media than OvaScience. MarketBeat recorded 1 mentions for FibroGen and 0 mentions for OvaScience. OvaScience's average media sentiment score of 0.35 beat FibroGen's score of 0.00 indicating that FibroGen is being referred to more favorably in the media.
FibroGen has a net margin of -143.57% compared to FibroGen's net margin of -10,128.37%. OvaScience's return on equity of 0.00% beat FibroGen's return on equity.
FibroGen has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, OvaScience has a beta of 3.11, indicating that its stock price is 211% more volatile than the S&P 500.
FibroGen presently has a consensus target price of $17.00, indicating a potential upside of 1,316.67%. Given OvaScience's higher probable upside, equities research analysts clearly believe FibroGen is more favorable than OvaScience.
FibroGen received 69 more outperform votes than OvaScience when rated by MarketBeat users. However, 63.87% of users gave OvaScience an outperform vote while only 62.36% of users gave FibroGen an outperform vote.
72.7% of FibroGen shares are owned by institutional investors. Comparatively, 22.5% of OvaScience shares are owned by institutional investors. 2.0% of FibroGen shares are owned by insiders. Comparatively, 7.4% of OvaScience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
OvaScience has lower revenue, but higher earnings than FibroGen.
Summary
FibroGen beats OvaScience on 8 of the 14 factors compared between the two stocks.
Get OvaScience News Delivered to You Automatically
Sign up to receive the latest news and ratings for OVAS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OVAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OvaScience Competitors List
Related Companies and Tools
